Compare Alphabet Inc Class A (GOOGL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Sana Biotechnology Inc — how do they compare? Alphabet Inc Class A trades at $355.9 (market cap $4.52T), while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). The key difference: Alphabet Inc Class A is far larger — about 4575.2× Sana Biotechnology Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GOOGL | SANA | |
|---|---|---|
Market Cap | $4.52T | $987.94M |
Sector | Media | Health |
52-Week High | $402.62 | $5.92 |
52-Week Low | $182.97 | $2.68 |
Enterprise Value | $4.49T | $962.13M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $354.37, down 1.43% on the day, amid a bullish technical setup with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Financial health is solid, with 2025 revenue of $402.84 billion and net income of $132.17 billion, reflecting a net margin of 32.8%. Positive news flow highlights AI-driven growth and strategic partnerships.
Outlook remains positive given earnings momentum, AI expansion, and a consensus price target of $431.78 implying 22% upside. Risks include antitrust scrutiny and tech sector volatility. Institutional sentiment is strongly bullish with 85% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
